Lantern Pharma Inc.
LTRN
$1.79
$0.021.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -18.65M | -15.91M | -17.12M | -18.92M | -19.25M |
| Total Depreciation and Amortization | 146.40K | 128.50K | 110.50K | 241.20K | 191.30K |
| Total Amortization of Deferred Charges | 33.60K | 33.60K | -- | -- | -- |
| Total Other Non-Cash Items | 4.90M | 873.00K | 696.80K | 715.20K | 340.60K |
| Change in Net Operating Assets | -499.60K | -197.10K | 635.30K | 1.11M | 850.00K |
| Cash from Operations | -14.08M | -15.07M | -15.68M | -16.86M | -17.87M |
| Capital Expenditure | -600.00 | -600.00 | -1.80K | -4.90K | -7.30K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 9.17M | 12.07M | 11.06M | 16.21M | 10.97M |
| Cash from Investing | 9.17M | 12.07M | 11.06M | 16.21M | 10.96M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.63M | 1.64M | 1.64M | 971.80K | 12.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -139.70K | -139.70K | -139.70K | -- | -- |
| Cash from Financing | 5.49M | 1.50M | 1.50M | 971.80K | 12.00K |
| Foreign Exchange rate Adjustments | 19.60K | 48.20K | 33.40K | -36.80K | -20.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 598.90K | -1.46M | -3.09M | 286.70K | -6.92M |